I期临床-话题@MedSci

#I期临床#

570篇内容 | 7020人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653216, encodeId=4d951653216e3, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2021年10月23日简报：本轮本土疫情波及10省市，因为冷冻食品和动物可传播，源头追踪变得困难和复杂；欧亚多国疫情猛烈反弹，新冠新变种病毒AY 4.2.快速扩散，新一波疫情迹象出现；罗氏新冠药物合作方宣布新冠口服II期临床研究失败, objectType=article, longId=219098, objectId=f3742190989b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3742190989b, replyNumber=0, likeNumber=63, createdTime=2022-04-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3742190989b, moduleTitle=2021年10月23日简报：本轮本土疫情波及10省市，因为冷冻食品和动物可传播，源头追踪变得困难和复杂；欧亚多国疫情猛烈反弹，新冠新变种病毒AY 4.2.快速扩散，新一波疫情迹象出现；罗氏新冠药物合作方宣布新冠口服II期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3742190989b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653142, encodeId=ea891653142a1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=国药中生发布新冠灭活疫苗III期临床期中分析结果，保护效力79.34%【附点评】, objectType=article, longId=205020, objectId=fbac2050204d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbac2050204d, replyNumber=0, likeNumber=68, createdTime=2021-10-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbac2050204d, moduleTitle=国药中生发布新冠灭活疫苗III期临床期中分析结果，保护效力79.34%【附点评】, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbac2050204d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653154, encodeId=9e97165315467, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, objectType=article, longId=206516, objectId=fdf420651685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdf420651685, replyNumber=0, likeNumber=48, createdTime=2021-05-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdf420651685, moduleTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdf420651685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653150, encodeId=174c165315084, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：候选新冠肺炎疫苗Ad26.cov2-s I-II期临床研究获得成功, objectType=article, longId=205725, objectId=edf1205e25a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edf1205e25a9, replyNumber=0, likeNumber=79, createdTime=2021-06-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edf1205e25a9, moduleTitle=NEJM：候选新冠肺炎疫苗Ad26.cov2-s I-II期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edf1205e25a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653208, encodeId=8ded1653208a5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, objectType=article, longId=217525, objectId=c79c21e52563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c79c21e52563, replyNumber=0, likeNumber=75, createdTime=2022-08-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c79c21e52563, moduleTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c79c21e52563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653212, encodeId=1196165321241, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , objectType=article, longId=218140, objectId=973121814015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=973121814015, replyNumber=0, likeNumber=0, createdTime=2022-04-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=973121814015, moduleTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=973121814015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653220, encodeId=50e91653220ab, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, objectType=article, longId=220461, objectId=b29d2204611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d2204611e, replyNumber=0, likeNumber=77, createdTime=2022-07-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d2204611e, moduleTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29d2204611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653172, encodeId=a8b116531e2ae, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果, objectType=article, longId=209280, objectId=187220928040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=187220928040, replyNumber=0, likeNumber=69, createdTime=2021-05-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=187220928040, moduleTitle=Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=187220928040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653140, encodeId=396d16531403d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, objectType=article, longId=204948, objectId=3cf1204948c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf1204948c8, replyNumber=0, likeNumber=78, createdTime=2021-06-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf1204948c8, moduleTitle=患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cf1204948c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653133, encodeId=6770165313356, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=国内**新冠病毒重组蛋白亚单位疫苗启动III期临床, objectType=article, longId=204110, objectId=3247204110d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3247204110d5, replyNumber=0, likeNumber=0, createdTime=2021-07-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3247204110d5, moduleTitle=国内**新冠病毒重组蛋白亚单位疫苗启动III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3247204110d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653162, encodeId=1d2a165316277, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, objectType=article, longId=207295, objectId=aa7320e295db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7320e295db, replyNumber=0, likeNumber=77, createdTime=2021-02-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7320e295db, moduleTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7320e295db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653143, encodeId=7aa01653143f2, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, objectType=article, longId=205036, objectId=8f5c20503649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5c20503649, replyNumber=0, likeNumber=71, createdTime=2021-05-10, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5c20503649, moduleTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f5c20503649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653153, encodeId=60181653153a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=脱发新疗法！FOL-005的II期临床研究已接近尾声, objectType=article, longId=206428, objectId=acf720642822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acf720642822, replyNumber=0, likeNumber=97, createdTime=2021-08-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acf720642822, moduleTitle=脱发新疗法！FOL-005的II期临床研究已接近尾声, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acf720642822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653137, encodeId=62a8165313e1b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=中国艾滋病疫苗或明年开启III期临床试验，有望突破HIV困局, objectType=article, longId=204745, objectId=8fbc204e4566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fbc204e4566, replyNumber=0, likeNumber=77, createdTime=2021-11-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fbc204e4566, moduleTitle=中国艾滋病疫苗或明年开启III期临床试验，有望突破HIV困局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fbc204e4566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653130, encodeId=3356165313013, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持, objectType=article, longId=203842, objectId=f57420384247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f57420384247, replyNumber=0, likeNumber=0, createdTime=2021-11-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f57420384247, moduleTitle=“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f57420384247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653207, encodeId=69f1165320e50, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, objectType=article, longId=217312, objectId=e46321e31264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46321e31264, replyNumber=0, likeNumber=77, createdTime=2022-03-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46321e31264, moduleTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46321e31264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653171, encodeId=e93d16531e17c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, objectType=article, longId=209159, objectId=3dc92091590c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc92091590c, replyNumber=0, likeNumber=60, createdTime=2021-07-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc92091590c, moduleTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc92091590c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653155, encodeId=64ba1653155ce, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lenzilumab治疗COVID-19住院患者，即将开展III期临床, objectType=article, longId=206522, objectId=76e2206522a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76e2206522a7, replyNumber=0, likeNumber=77, createdTime=2021-09-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76e2206522a7, moduleTitle=Lenzilumab治疗COVID-19住院患者，即将开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76e2206522a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破, objectType=article, longId=209998, objectId=35c620999849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c620999849, replyNumber=0, likeNumber=60, createdTime=2022-01-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c620999849, moduleTitle=首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35c620999849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653165, encodeId=bd6e165316533, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, objectType=article, longId=207999, objectId=50a420e99915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50a420e99915, replyNumber=0, likeNumber=116, createdTime=2021-12-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50a420e99915, moduleTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50a420e99915)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2021年10月23日简报：本轮本土疫情波及10省市，因为冷冻食品和动物可传播，源头追踪变得困难和复杂；欧亚多国疫情猛烈反弹，新冠新变种病毒AY 4.2.快速扩散，新一波疫情迹象出现；罗氏新冠药物合作方宣布新冠口服II期临床研究失败

2022-04-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

国药中生发布新冠灭活疫苗III期临床期中分析结果，保护效力79.34%【附点评】

2021-10-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募

2021-05-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：候选新冠肺炎疫苗Ad26.cov2-s I-II期临床研究获得成功

2021-06-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索

2022-08-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST

2022-04-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505

2022-07-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果

2021-05-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

患者招募：重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌（NSCLC）的II/III期临床研究

2021-06-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

国内**新冠病毒重组蛋白亚单位疫苗启动III期临床

2021-07-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验

2021-02-24

zhouqu_8 (审核中...)

前往app查看评论内容

#I期临床#

合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验

2021-05-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

脱发新疗法！FOL-005的II期临床研究已接近尾声

2021-08-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

中国艾滋病疫苗或明年开启III期临床试验，有望突破HIV困局

2021-11-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持

2021-11-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究

2022-03-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始

2021-07-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lenzilumab治疗COVID-19住院患者，即将开展III期临床

2021-09-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破

2022-01-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果

2021-12-26

科室
- - 订阅+
  - 更多科室
工具
服务